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Background: Multiple myeloma is an incurable haematological cancer that affects physical, psychological and
social domains of quality of life (QOL). Treatment decisions are increasingly guided by QOL issues, creating a need
to monitor QOL within clinical practice. The development of myeloma-specific QOL questionnaires has been limited
by a paucity of research to fully characterise QOL in this group. Aims of the present study are to (1) explore the issues
important to QOL from the perspective of people with multiple myeloma, and (2) explore the views of patients and
clinical staff on existing QOL questionnaires and their use in clinical practice.
Methods: The ‘Issues Interviews’ were semi-structured qualitative interviews to explore the issues important to
QOL in a purposive sample of myeloma patients (n = 20). The ‘Questionnaire Interviews’ were semi-structured qualitative
interviews in a separate purposive sample of myeloma patients (n = 20) to explore views on existing QOL questionnaires
and their clinical use. Two patient focus groups (n = 7, n = 4) and a focus group of clinical staff (n = 6) complemented
the semi-structured interviews. Thematic content analysis resulted in the development of a theoretical model of QOL
in myeloma.
Results: Main themes important to QOL were Biological Status, Treatment Factors, Symptoms Status, Activity &
Participation, Emotional Status, Support Factors, Expectations, Adaptation & Coping and Spirituality. Symptoms had an
indirect effect on QOL, only affecting overall QOL if they impacted upon Activity & Participation, Emotional Status or
Support Factors. This indirect relationship has implications for the design of QOL questionnaires, which often focus on
symptom status. Health-service factors emerged as important but are often absent from QOL questionnaires. Sexual
function was important to patients and difficult for clinicians to discuss, so inclusion in clinical QOL tools may flag
hidden problems and facilitate better care. Patients and staff expressed preferences for questionnaires to be no
more than 2 pages long and to include a mixture of structured and open questions to focus the goals of care on
what is most important to patients.
Conclusion: Existing QOL questionnaires developed and validated for use in myeloma do not capture all that is
important to patients and may not be well suited to clinical use.
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Multiple myeloma is a malignant proliferation of plasma
cells affecting 0.4 to 5 per 100,000 individuals per year
globally, with a higher incidence in developed countries
and slowly increasing incidence worldwide [1]. The pattern
of end-organ damage is complex, including destruction
of the bones, bone marrow failure and renal failure,
leading to impairments in physical, psychological and
social domains of quality of life (QOL) [2-4]. Whilst
myeloma remains incurable the survival of patients has
significantly improved in the course of the last 15 years
as a result of increased availability of more active and
less toxic drugs [5]. However, toxicity remains an issue
and patients are living longer with complications of
their disease and side effects of treatment. New drug
trials and treatment decisions are therefore increasingly
dictated by considerations around QOL.
A number of models of QOL have been reported
throughout the literature. These include those based on
human need [6]; expectations [7]; functioning, disability
and health [8]; personal characteristics as mediators [9];
and phenomenological models based on individual per-
ceptions [10]. A model of QOL for use in healthcare was
proposed by Wilson and Cleary [11], which provides a
taxonomy of five levels of heath outcome for use across
different diagnoses: biological and physiological factors;
symptoms; functioning; general health perceptions; and
overall QOL. Wilson and Cleary linked familiar biological
variables to overall QOL, to demonstrate how clinical
interventions might be better designed to improve QOL,
through modification of the intervening variables. A recent
systematic review found Wilson and Cleary’s model to be
the most widely used in the literature [12].
There are a number of QOL questionnaires validated
for use in myeloma [13], but only two myeloma-specific
tools have been developed. The European Organisation
for Research and Treatment of Cancer core cancer ques-
tionnaire (EORTC-QLQ-C30) and its myeloma-specific
module (MY20) are the most comprehensively validated
and were designed predominantly as research tools [13-16].
The only other myeloma-specific QOL questionnaire is
the recently developed Functional Assessment of Can-
cer Therapy – Multiple Myeloma (FACT-MM), although
its item pool was developed with limited patient involve-
ment and its authors call for further development work
using larger and more heterogeneous patient samples [17].
Assessment of QOL is important in both research and
clinical practice. Alongside clinical care, QOL assessment
can monitor response to treatment, focus goals of care,
and facilitate communication [18-21]. Several authors
have recommended that QOL assessment should form
part of the routine care of myeloma patients [2,3,22],
yet existing QOL questionnaires may not be well suited
for this purpose, and may not capture all the issuesimportant to patients [13]. Qualitative enquiry is a vital
step to ensure good content validity during the develop-
ment of QOL questionnaires [23,24]. There are some
qualitative studies looking at the experience of myeloma
from the patient’s perspective. These have explored lived
experience [25-28], trauma and post-traumatic growth
[29] and distress [30], but there is a paucity of qualitative
research to directly characterise the meaning of QOL in
this group [13].
This study is part of a research programme to investi-
gate ways to improve QOL assessment in clinical practice.
The aims of the current study are (1) to explore the issues
important to QOL from the perspective of people diag-
nosed with multiple myeloma, and (2) to explore the views
of patients and clinical staff on existing QOL question-
naires and their use in clinical practice.
Methods
Overview of study design
This study is reported in accordance with the RATS
guidelines for qualitative research [31]. The study used a
combination of semi-structured qualitative interviews
and focus groups to address the overall aims. The ‘Issues
Interviews’ were semi-structured interviews of myeloma
patients (n = 20) to explore the issues important to QOL
from the patients’ perspective. The ‘Questionnaire Inter-
views’ were semi-structured interviews in a separate
sample of myeloma patients (n = 20) to explore views on
existing QOL questionnaires in terms of content, design
and preferences for clinical use. The semi-structured inter-
views were complemented by two patient focus groups
(n = 7, n = 4). Each patient focus group was split in two
halves to mirror the Issues Interviews and Questionnaire
Interviews – the first half of each focus group explored
issues important to QOL, and the second half explored
views on existing QOL questionnaires. Finally, a focus
group of clinical staff (n = 6) explored views on existing
QOL questionnaires, and the desired clinical utility of
such tools in routine practice.
The combined use of individual interviews and focus
groups is recommended best practice for establishing
content validity in both new and existing patient reported
outcome measures [23]. The combined use of these
methods helps confirm the validity of results through
triangulation [32]. In the present study, individual inter-
views were carried out to allow greater depth of probing
and offer privacy for the discussion of sensitive QOL
issues that may be hard to raise in a group setting (such
as psychological problems or sexual function). Focus
groups were also carried out since group discussion
may ignite different memories and ideas for individual
participants, with new or additional themes emerging
from group interaction. For these reasons, the two
interview methods were considered to be required and
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questions were asked of participants within the two
different interview types.
Participants and setting
Participants were recruited from both inpatient and
outpatient settings across three organisations in inner
London. The lead site was King’s College Hospital NHS
Foundation Trust, with additional participants recruited
from Guy’s and St Thomas’ NHS Foundation Trust and St
Christopher’s Hospice to ensure a balance from different
clinical settings and stages of disease. King’s College and
Guy’s and St Thomas’ Hospital Trusts provide tertiary
haemato-oncology services to London and south-east
England, and King’s contains the largest bone marrow
transplant centre in Europe. St Christopher’s is one of the
UK’s largest hospices, offering inpatient and community
hospice care to people across 5 boroughs in south-east
London.
Patients could participate in only one interview or
focus group across the whole study. Inclusion criteria for
patients were age 18 years or older; confirmed diagnosis
of multiple myeloma; having been told the diagnosis;
and capacity to give written informed consent. Exclusion
criteria for patients were those too unwell, symptomatic
or distressed to participate (as judged by the clinical
team); severe neutropenia where contact with researcher
may pose a risk; unable to understand written and spoken
English; and those for whom myeloma was not the most
important health problem (as judged by the patient).
Inclusion criteria for clinical staff were those with at
least 2 years’ experience working regularly with myeloma
patients in the specialist haematology setting.
During recruitment all potential participants were
screened by a member of their clinical team to assess
eligibility before being approached about the study.
Following the initial approach, potential participants
were offered at least 24 hours to consider if they wanted
to take part. Participation was voluntary and interviews
took place at a time and place convenient to participants
(hospital, home or other location requested by them),
except for focus groups which took place on the hos-
pital site.
Recruitment was carried out by a team of three research
staff from the Department of Palliative Care, Policy and
Rehabilitation at King’s College London (TRO, CR and
SdW). TRO was a clinical research fellow with a back-
ground as a medical doctor in both haematology and
palliative medicine, CR was a research assistant with a
background in psychology, and SdW was a research
nurse with a background in oncology and palliative care
nursing. The research team was distinct from the clinical
team – none of the researchers were involved in the
clinical care of study participants. The research teamintroduced themselves to patients as ‘researchers’ to avoid
any potential coercion when deciding whether or not to
participate, and reduce any potential bias in study partici-
pants’ responses during the interviews.
Sampling
Both the Issues Interviews and Questionnaire Interviews
used purposive sampling by gender, age (<65 or >65),
ECOG performance status (0–2 or 3–4) and disease
phase (newly diagnosed, plateau, or relapsed) [33]. These
criteria were chosen to achieve maximum variation across
key characteristics thought to potentially influence QOL,
based on existing literature. Sample size was not fixed
at the start, but was based on data saturation and the
purposive criteria. Data saturation was defined as two
consecutive interviews with no new emergent themes
or issues important to QOL, and was recorded using
saturation tables as recommended in the development
of patient reported outcomes research [34].
For the patient focus groups convenience sampling was
used. There were many practical difficulties in gathering
patients together as a group, with rapidly changing treat-
ment plans and people unable to travel long distances.
The number of patient focus groups was not decided at
the outset, but was continued until no new QOL issues
or themes emerged from two consecutive groups. For
the clinician focus group a purposive sample was used
to ensure a balance of different professional groups and
levels of seniority (senior and junior doctors; senior and
junior nurses; allied health professionals). Only one
focus group of clinical staff was carried out due to the
practical challenges of gathering a multidisciplinary group
together.
Issues interviews
These took place in a private room with only the inter-
viewer and participant present to help reduce any potential
bias in the participants’ responses. The interview topic
guide was split into two halves, covering (i) what issues
are important to QOL; and (ii) what things impact on
QOL. In practice, these two halves were not distinct,
and the course of the interview was guided by the par-
ticipant’s responses. All interviews began with open
questions, with leading questions avoided throughout.
Participants were probed about specific QOL issues only
if they were raised in response to an open question.
This meant the discussion was based only on the issues
important to participants.
The Issues Interviews were all conducted by a single
researcher (TRO). Interviews were audio recorded and
transcribed verbatim. Transcription was split between TRO
and a professional transcriber. All professional transcripts
were read by TRO alongside the recording to check for
accuracy prior to analysis.
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Each participant was asked to complete four QOL ques-
tionnaires. These were EORTC-QLQ-C30, its myeloma
module (MY24), the Palliative care Outcome Scale (POS)
and a single item global QOL question using a visual
analogue scale from 0 to 100.
The EORTC-QLQ-C30 and MY24 are 30- and 24-item
tools respectively, which together form a 54-item tool.
These were chosen as the most comprehensively validated
tools in patients with myeloma [13,15,16]. The MY24
module has been revised to the MY20 by removal of 4
items by the EORTC group, who currently recommend
the revised MY20 for use. We chose to use the MY24 at
the outset of the current study, since the 4 items were
removed due to poor psychometric performance (ceiling
effects), rather than a belief that they are not important to
QOL [14]. It was therefore considered important to assess
participants’ views towards the QOL issues covered by the
4 removed items.
The POS was added as a comparator since it is shorter
(12 items) and was designed for clinical use (as opposed
to the EORTC tools, which were primarily designed for
use in research settings). A systematic review of existing
QOL questionnaires validated in myeloma did not identify
any tools specifically designed for clinical use [13], so the
POS was selected to allow exploration of participants’
views on such tools. The POS was developed for use in
people with palliative care needs irrespective of diagnosis
or clinical setting, and is suitable for use in those diag-
nosed with chronic or progressive diseases [35,36], making
it appropriate for use by myeloma patients.
The EORTC and POS questionnaires contain a mixture
of numerical and Likert scales, with a single open question
in the POS. The single item visual analogue scale was
therefore added to allow preferences to be explored
around this additional type of scaling.
Participants completed and were asked about each
questionnaire in turn. They were asked if each item was
important or relevant to their QOL and about the most
important items, missing items (important QOL issues
not covered), acceptable questionnaire length for use in
routine clinical practice and preferences for layout, scaling
and response options. The Questionnaire Interviews were
completed by one of three researchers (TRO, CR or SdW).
They were not transcribed but were analysed directly from
the audio recordings [37].
Focus groups
All focus groups were chaired by TRO and were audio
recorded. Participants were identified by name so the
data could be analysed at the level of the individual.
Patient focus groups were each split into two halves, the
first half mirroring the Issues Interviews and the second
half mirroring the Questionnaire Interviews. There wasa break in between the two halves during which the
participants completed the same set of questionnaires
as for the Questionnaire Interviews.
The focus group of clinical staff explored views towards
the same set of QOL questionnaires shown to patients in
the Questionnaire Interviews. This focus group explored
perspectives on routine clinical use, preferred utility of
QOL tools in clinical practice, most clinically relevant
questions, preferred layout, presentation and response
formats. The topic guide used the guiding questions sug-
gested elsewhere [38]: (i) What are the issues frequently
discussed by myeloma patients and clinical staff; (ii) are
there important issues less frequently addressed; (iii)
can these issues be addressed using questionnaires; (iv)
what is the clinical value of QOL questionnaires; and
(v) suggestions for improving existing QOL questionnaires
to make them more useful in clinical practice. The focus
group of clinical staff was analysed directly from the audio
recording.
Analysis
The Issues Interviews and corresponding half of each
patient focus group were analysed together. They were
transcribed verbatim, imported into NVivo software and
analysed using thematic content analysis [39,40]. Data
analysis took place alongside recruitment so emergent
themes could guide sampling and probing in future
interviews. The first transcripts were analysed and an
initial coding frame was developed by TRO. To reduce
bias, a second researcher (CR) double-coded the complete
set of transcripts. Both TRO and CR coded all transcripts
alongside recruitment and met regularly to discuss any
refinements to the coding frame as the study progressed.
Once recruitment was complete and the coding frame
finalised, TRO re-coded the complete set of transcripts
according to the final coding frame. CR then re-coded a
subset (10%) using the final coding frame, to check for
consistency. Discrepancies were resolved by consensus.
The Questionnaire Interviews, corresponding half of
each patient focus group, and the professional focus group
were all analysed together. Data were extracted directly
from the audio into tables, constructed with participant
numbers across the top, and questionnaire items/attributes
listed down the left hand column. Examples of attributes
of interest were font size, questionnaire length, response
options and scaling, recall period, most important ques-
tions, missing items or gaps, other comments. After the
table was populated analysis could take place ‘by-item’ or
‘by-attribute’ where all views could be considered in aggre-
gate. Data were extracted into tables by TRO and CR, with
further analysis/aggregation of the data carried out by TRO.
Throughout this process TRO developed a theoretical
model of QOL based on the issues and themes emerging
from the data. The model was developed by taking
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and models of QOL from the literature. It was not clear
at the outset if an existing model would be modified or
if a completely new model would be required, but it was
considered important to take account of existing work and
build on this where appropriate, rather than ‘re-inventing
the wheel’. The model mainly drew on data from the Issues
Interviews and corresponding half or each focus group, but
did also incorporate some data from the Questionnaire
Interviews (e.g. views about missing questionnaire items
important to QOL). The model was regularly discussed
with the wider project steering group throughout its
development, comprising three junior researchers with
backgrounds in medicine (TRO), psychology (CR) and
nursing (SdW), and a professor of haematology (SAS)
and professor of palliative care (IJH).
Ethical issues
Research Ethics Committee approval was granted by
the South East London REC-3 (ref 10/H0808/133). All
participants gave written informed consent to take part,
including for their anonymised views to be shared in
scientific publications and meetings. Care was taken to




74 eligible patients were approached and 51 agreed to
participate (45 from King’s College Hospital, 4 from St
Christopher’s Hospice and 2 from Guy’s Hospital). The
majority of participants were recruited from King’s College
Hospital due to earlier Research and Development approval
to recruit from this site. Reasons for declining were a
reluctance to share personal experiences with others
(7), feeling too unwell (4), being too busy (3), previous
bad experiences with research (1), living too far away
(1), and no reason given (7). Characteristics of recruited
patients are shown in Table 1.
9 clinical staff were approached (all from King’s College
Hospital), and 6 agreed to participate. All staff who declined
did so due to clinical commitments. Characteristics of
recruited staff are shown in Table 2.
Participants were recruited over a 20-month period. The
Issues Interviews recruited over months 1–16, Question-
naire Interviews over months 11–20; and focus groups over
months 14–19. The mean length of the Issues Interviews
was 52 minutes, Questionnaire Interviews 73 minutes, and
focus groups 117 minutes.
For the Issues Interviews theoretical saturation was
reached after 14 participants. However, only 5 of the first
14 participants had an ECOG performance of 3–4, and
early analysis revealed that functional status may be an
important determinant of QOL. Therefore recruitmentwas continued to target more participants with poor
performance status. Two new issues emerged in the
18th interview, and recruitment was stopped after 20
participants. The Questionnaire Interviews yielded no
additional QOL issues, so recruitment was continued
to 20 interviews once a balance of the purposive criteria
had been reached. No new QOL issues emerged in the
patient focus groups so recruitment was stopped after
two groups.
Issues important to QOL
The term ‘QOL’ was understood by all participants, with
none asking for clarification of its meaning. During the
Issues Interviews (and corresponding half of each focus
group) health-related issues dominated the discussion in
most cases. This was true even though more general
questions were asked (“What things are important to
your QOL?”). Participants raised a total of 80 issues that
were important or affecting QOL. These were grouped
into 9 main themes: Biological Status, Treatment Factors,
Symptom Status, Activity & Participation, Emotional
Status, Support Factors, Expectations, Adaptation & Coping
and Spirituality. Examples from the data showing how
each theme relates to overall QOL are shown in Figure 1.
The themes most closely related to QOL were Emotional
Status, Activity & Participation and Support Factors. A
change in any of these seemed to lead directly to a change
in QOL. Rather than impacting on QOL, these themes
seemed to form the essence of QOL itself (Figure 1).
Within Support Factors, there was a particularly strong
role for health-service factors. Every participant in the
Issues Interviews mentioned some property of the health-
service as being important to their QOL, and this
sometimes dominated the discussion.
The themes of Biological Status, Treatment Factors and
Symptoms Status were important to QOL, but less closely
related. These themes were often raised by participants,
but further probing revealed that they did not necessarily
affect QOL. Biological Status, Treatment Factors and
Symptoms Status only affected QOL if they affected
one of the more fundamental themes ‘closer’ to QOL
(Emotional Status, Activity & Participation or Support
Factors) (Figure 1).
Expectations, Adaptation & Coping and Spirituality had a
more complex relationship to QOL. These were personal
characteristics that governed how much a problem affected
QOL for a given individual. Examples from the data are
shown in Figure 2. Taking the first example under Expecta-
tions (Figure 2), this participant reported a reduction in
QOL because the illness was preventing him from walking,
travelling and socialising, but the impact of these functional
impairments on QOL seemed to be driven partly by the
individual’s expectation that these activities would be
possible during their retirement. By contrast, some
Table 1 Sample characteristics (patients, n = 51)
Study components Total
(n = 51)Issues interviews (n = 20) Questionnaire interviews (n = 20) Patient focus groups (n = 11)
Gender
Male 10 12 8 30
Female 10 8 3 21
Age
Median (range) 66 (41–78) 63.5 (46–81) 60 (41–70) 64 (41–81)
<65 10 12 6 27
≥65 10 8 5 24
Marital status
Single 0 2 1 3
Married/partnered 14 15 9 38
Divorced/separated 3 2 1 6
Widowed 3 1 0 4
Ethnicity
White British 13 12 9 34
White Other 1 1 0 2
Black African/Caribbean 5 5 2 12
Other 1 2 0 3
Religion
Atheist 4 0 0 4
Christian 16 17 11 44
Other 0 3 0 3
Highest educational level
Did not finish school 3 0 3 6
Secondary school graduate 5 9 3 17
College/technical qualification 9 9 2 20
First degree 2 1 3 6
Higher degree 1 1 0 2
Occupation status
Working or student 3 5 1 9
Not working 3 3 2 8
Retired 14 12 8 34
ECOG performance status
0-2 10 11 11 32
3-4 10 9 0 19
Disease phase
Newly diagnosed 7 6 0 13
Stable/plateau phase 7 7 9 23
Relapsed/progressive 6 7 2 15
Currently on treatment
Yes 7 13 3 23
No 13 7 8 28
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Table 1 Sample characteristics (patients, n = 51) (Continued)
Study components Total
(n = 51)
Issues interviews (n = 20) Questionnaire interviews (n = 20) Patient focus groups (n = 11)
Months since diagnosis
0-12 8 8 1 17
13-24 7 1 1 9
25-36 2 0 0 2
37-48 1 4 1 6
Over 48 2 7 8 17
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had not affected their QOL, because they had managed
to adapt to live life differently (see examples under
Adaptation & Coping, Figure 2). For some participants
it was their faith in God that provided the strength and
hope needed to cope with their illness, or provide support
in the form of doctors, wisdom and knowledge. Faith in
God acted for some participants like a lens through which
all experience was viewed, with examples shown under
the theme of Spirituality (Figure 2).
Development of the theoretical model of QOL
The theoretical model of OQL developed in the present
study sought to represent the relationships between
overall QOL and the themes identified above. The model
of QOL proposed by Wilson and Cleary [11] was adapted,
since it was designed to link clinical variables to QOL
and seemed a good fit for many of the themes emerging
from the data. The adapted theoretical model of QOL in
myeloma is shown in Figure 1. The boxes in the model
correspond to the themes identified above, and the lists
within each box show the issues raised by participants





Median (range) 37 (32–61)
Time since qualification
Years in clinical practice: Median (range) 11 (5–38)
Years in haematology: Median (range) 8.5 (3–30)
Profession group and grade
Medical: Haematology consultant (myeloma specialist) 1
Medical: Haematology junior doctor (specialist registrar) 1
Nursing: Myeloma clinical nurse specialist 1
Nursing: Haematology ward based 2
Allied health: Haematology specialist physiotherapist 1The lines linking the boxes/themes represent recipro-
cal causal relationships, acting in both directions. A
change in Biological Status may cause a change Symp-
toms Status (e.g. fractures causing pain), but the converse
may also be true and a change in Symptoms Status may
cause a change Biological Status (e.g. vomiting causing renal
failure). The intersections of the lines in the model create
junctions where causal relationships can travel in any direc-
tion – representing the interconnectedness of the themes.
For example, a change in Treatment Factors might affect
Emotional Status, Symptom Status and Activity and Parti-
cipation (chemotherapy causing mood swings, peripheral
numbness and impaired sexual function – Figures 1 and 3).
The boxes/themes for Emotional Status, Activity & Partici-
pation and Support Factors have direct connections to QOL,
but this is not the case for Biological Status, Treatment Fac-
tors and Symptoms Status. This signifies that changes in
Emotional Status, Activity & Participation and Support Fac-
tors led directly to changes in QOL, whereas changes in Bio-
logical Status, Treatment Factors and Symptoms Status only
affected QOL if one of the three more fundamental themes
‘closer’ to QOL was also affected (Figures 1 and 3).
The overarching box represents the themes of Adapta-
tions & Coping, Expectations and Spirituality. These had
a more complex relationship to overall QOL, acting to
mediate the causal relationships between themes. For
example, the degree to which reduced mobility affected
QOL being determined by the individual’s expectations,
illness adaption, and spiritual beliefs (Figures 2 and 3).
Views on existing QOL questionnaires
During the Questionnaire Interviews (and corresponding
half of each focus group) participants often found it diffi-
cult to identify the most important items, since they found
it difficult to consider so many questions in aggregate. Out
of 31 participants who were shown the questionnaires,
only 6 were able to state the most important items. Out of
these 6, most participants highlighted more than one item
as important, and the same issues tended to recur.
The items raised as important were mobility (5 partic-
ipants), pain (3 participants), healthcare (2 partici-
pants) and dying (1 participant). Similar difficulties
Figure 1 The relationship of biological status, treatment factors, symptom status, emotional status, activity & participation, and
support factors to overall QOL.
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Figure 2 The role of expectations, spirituality, adaptation and coping in determining QOL.
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missing issues, with only 9 participants giving a response.
Again, the same issues tended to recur: healthcare
(5 participants), information about the future (3 partici-
pants), sexual function (3 participants) and independ-
ence (2 participants).
Participants commented that some questions in existing
tools were vague and hard to interpret (e.g. “Did you need
to rest?” and “Have you felt ill?”); and some words were
hard to understand (“Have you felt nauseated?”). A number
of participants complained that questions appeared to over-
lap in their meaning, (“Did you need to rest?/Were you
tired?”, “Did you worry/Did you feel tense?”). Acceptabilityof existing tools was reduced where there was perceived
repetition, for example multiple questions about pain.
Participants were asked about the ideal length for a
questionnaire. This was intended to be a question about
the acceptable number of items, but participants usually
gave their response in terms of the number of pages or
amount of text to read. Some participants noted that the
EORTC tools felt less burdensome than the POS be-
cause the response options were the same for multiple
items in the EORTC, whereas the POS has different
response options for each question. This meant that com-
pletion of the EORTC involved less reading, even though it
contains more items. Participants framed their preferences
Figure 3 Theoretical model of the QOL of people with multiple myeloma. Adapted from Wilson and Cleary [11].
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that extended to no more than 2 sides of A4 paper.
There were mixed views on the best type of scaling
(Likert vs. numerical scales), although there was a dislike of
the visual analogue scale by all participants due to difficulty
understanding how to complete it and generally needing
more explanation and prompting. The EORTC asks the re-
spondent to consider the past week, whereas the POS asks
about the past 3 days. Many participants had no preference
about this. All those expressing a preference preferred
1 week or longer. Recall was easier over the past week than
over 3 days. Some participants noted that questions about
healthcare or relationships with doctors did not make sense
over a fixed time frame, and were something that evolved
over the whole of their illness experience. All participants
supported the inclusion of an open question (as found in
the POS), to allow them to raise issues not covered else-
where in the questionnaire.Focus group of clinical staff
The focus group of clinical staff identified a number of
desired uses for QOL tools in clinical practice. These were
to identify and prioritise problems from the patient’s per-
spective, mitigate against time pressure in busy clinical
settings, facilitate discussion of embarrassing issues, com-
pare QOL to before treatment started, trigger referral to
other services, and to aggregate data for clinical audit and
allocation of resources:
"Do all the people we treat in a certain way end up
with a particular problem? … if it is, then we've got to
do something about it” (Haematology doctor)
The most clinically useful questions from the profes-
sionals’ point of view were about anxiety, depression, pain,
fatigue, and sexual function. There was consensus that
sexual function is an important problem in myeloma,
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and might therefore be useful in a questionnaire to help
broach the subject:
"I do think it's an important issue for patients, but
obviously for some people it's an embarrassing one to
bring up…and it might be that you can't solve the
problem…but for some patients it's a very simple 'how
many platelets do I need to have sex?" (Physiotherapist)
All professionals in the focus group preferred the layout
of the EORTC tools. This was due to questions having the
same response options, making it easier to assimilate
information and focus on the problem areas when glan-
cing at the page. There was also consensus that the open
question in the POS would be clinically useful, since this
would allow patients to highlight any issues of concern
that were not specifically asked in the questionnaire.
Discussion
Myeloma patients are living longer with the complications
of their disease and side effects of treatment. With treat-
ment decisions increasingly guided by QOL concerns it is
becoming more important to monitor QOL as part of
routine clinical care. This is the first study to report a
theoretical model of QOL in multiple myeloma, and
the first report of the preferences of myeloma patients
and clinical staff for the design and clinical utility of QOL
questionnaires. These findings provide a platform from
which to develop or refine QOL questionnaires for use
within the clinical care of myeloma patients.
Symptoms and QOL
This study helps to characterise the role of symptoms in
determining the QOL of myeloma patients. Symptoms
were commonly reported by participants as affecting QOL,
although only by impacting on other issues (Emotional
Status, Activity & Participation, Support Factors). There
is clear utility for symptom items in clinical QOL tools,
where they might uncover hidden problems and help
prioritise or monitor changing symptoms over time. One
impact of these findings is that QOL questionnaires
should be designed to probe beyond a simple assessment
of symptom status (“What is your current level of pain
from 1 to 10?”), and instead ask for an evaluation of symp-
tom impact (“How much does pain currently interfere with
your life from 1 to 10?”). This principle is supported by
psychometric studies demonstrating that health status and
QOL are related but distinct constructs [41,42] – health
status alone does not capture all of QOL.
The distinction between ‘health status’ and ‘health evalu-
ation’ when developing QOL questionnaires has been
described previously [43]. Importantly, this difference
may affect the suitability of a questionnaire for use in agiven setting. For example, the desired utility of a QOL
questionnaire in a drug trial may be to identify the
prevalence of adverse events (side effects) and detect
differences between treatment arms. For this purpose
health status questions may be better suited [44]. However,
the present study suggests that QOL is better captured by
asking respondents to evaluate the impact of symptoms on
their life. A recent systematic review identified 13 QOL
questionnaires developed or validated for use in myeloma,
although most were designed for use in research and
focussed on health status, with only a minority asking for
health evaluations [13]. This builds a case for further work
to refine or develop new QOL tools focussing on health
evaluations, which may be better suited to clinical use
in people with multiple myeloma. There may also be
implications in health economics, where health status
questionnaires are the primary tool used in the generation
of quality adjusted life years (QALYs) and the allocation of
health resources [45], although such tools may not capture
all that is important to QOL.Health-service issues and QOL
The present study demonstrates the importance of health-
service issues in determining the QOL of myeloma patients.
Such issues have also been reported as important in other
qualitative studies in myeloma [26,27,29,30], making a case
for the inclusion of related items in myeloma QOL ques-
tionnaires. The EORTC-QLQ-C30 is the most extensively
validated QOL questionnaire for use in myeloma [13],
but contains no items about health-service issues. Its
accompanying myeloma-specific module (the MY24)
initially included 4 such items [15], but subsequent
psychometric validation resulted in all 4 being removed
due to poor psychometric performance (ceiling effects),
and the module was revised to the MY20 [14]. The FACT-
MM is another myeloma-specific questionnaire that also
has no questions about health service factors, though its
authors recognise that few patients were involved in its
development, and call for more development work using
larger patient samples [17].Sex and QOL
Sex was identified as important to QOL and impacted
by myeloma. Clinical staff identified sex as an important
clinical problem, but one that is difficult to discuss with
patients. This makes a case for including items about sex
in myeloma QOL tools both as an important component
of QOL, but also highlights an important clinical utility
in facilitating discussion about hidden problems. The
EORTC-QLQ-C30 +MY20 together do not contain any
items about sex, although this was considered during the
development of the myeloma module and is highlighted
as an area for future research [15]. The FACT-MM does
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satisfaction with their sex life.
Structure and design of clinical QOL tools
This study highlights a tension in the design of QOL
questionnaires, particularly for clinical use. Figure 1 lists
80 QOL issues that would be difficult to cover in 2 sides
of A4 (the maximum acceptable length identified here).
Acceptability to patients and staff is essential for any
clinical tool to be implemented [18,46], yet the need to
reduce burden on patients and staff conflicts with the
need to be comprehensive. A possible solution would be
to combine structured questions and open questions as
found in the POS questionnaire [35]. The POS open
question was popular amongst both patients and clinical
staff, and such questions also resonate with the need
for more individualised assessment alongside the use of
standard measures [38].
The findings presented here also suggest that the
acceptability of questionnaires to respondents and clin-
ical staff may be improved by using the same response
options for groups of items. This approach reduces the
amount of text for respondents to read and aids the
assimilation of information when interpreting completed
questionnaires.
Methodological issues and limitations
One of the limitations of this study is that the majority
of sampling took place at large treatment centres in
inner London, which may not be representative of the
country as a whole. Many patients had however travelled
to London from elsewhere in south-east England, and
were visiting the London hospitals for their tertiary
services. This is a normal service model in the UK, where
treatments such as bone marrow transplantation and
subsequent follow up are increasingly centralised.
Another sampling limitation is related to the single
focus group of clinical staff. Only one such focus group
was conducted due to practical challenges taking a multi-
disciplinary group away from the clinical service at the
same time. Further thoughts and ideas may have emerged
from additional focus groups of clinical staff.
The use of open questions in the Issues Interviews was
designed to elicit the issues most important to patients
without introducing bias from the interviewer. However,
the interviewer and primary author of the theoretical
model (TRO) had an awareness of many existing QOL
models at the outset of the study. This could be seen as
both a strength and a weakness. This approach allowed the
resulting model to build on existing theory, rather than
re-inventing the wheel. However, it must be acknowledged
that the model is a product of both the patients’ accounts
and the researcher’s own expertise and knowledge. The
model is an adaptation from Wilson and Cleary [11], butalso reflects the work of others. The distinction between
activity and participation was drawn from the World
Health Organisation’s model of functioning and disability
[47], later adapted to incorporate QOL [8]. The role of
expectations in determining QOL has been previously
described by Calman [7], and the role of adaptation
reflects the work of Schwartz and Sprangers on response
shift [48]. The role of spirituality and coping mechanisms
echoes the work of Zissi into personal characteristics as
mediators/determinants of QOL [9].
This study used both individual interviews and focus
groups to identify the issues important to QOL, which is
reported best practice when establishing content validity
of patient reported outcome measures [23]. For the
present study it could be argued that the patient focus
groups added little to the findings, since they yielded
no additional QOL issues beyond those identified in
the 20 Issues Interviews. However, the absence of any
new themes emerging from the patient focus groups
demonstrates that theoretical saturation was reached
independently of the chosen interview method (meth-
odological triangulation [32]).
Conclusions
This study presents the first detailed model of QOL in
people with multiple myeloma, alongside their preferences
for the design and clinical use of QOL questionnaires.
Existing questionnaires may not capture all that is import-
ant to QOL from the perspective of people with myeloma,
and often miss items on health service factors or sexual
function that are important to patients. Questionnaires for
use in the clinical care of myeloma patients should capture
the impact of symptoms on activity, participation or emo-
tional status, and avoid simply asking about symptom
status. Clinical questionnaires should not be more than 2
pages long and include open questions to give respon-
dents an individualised voice and focus the goals of care
on what is most important to patients. Further work is
needed to develop or refine existing QOL tools for use
in the clinical care of people with mutiple myeloma.
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